Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.65 USD
Change Today +0.0201 / 3.19%
Volume 77.5K
NBY On Other Exchanges
Symbol
Exchange
Berlin
NYSE Amex
As of 4:15 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

novabay pharmaceuticals inc (NBY) Snapshot

Open
$0.63
Previous Close
$0.63
Day High
$0.66
Day Low
$0.62
52 Week High
08/18/14 - $1.30
52 Week Low
02/27/15 - $0.42
Market Cap
39.8M
Average Volume 10 Days
209.1K
EPS TTM
$-0.32
Shares Outstanding
61.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVABAY PHARMACEUTICALS INC (NBY)

Related News

No related news articles were found.

novabay pharmaceuticals inc (NBY) Related Businessweek News

No Related Businessweek News Found

novabay pharmaceuticals inc (NBY) Details

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes topical non-antibiotic antimicrobial products for the eye care market. It operates through four segments: Dermatology, Ophthalmology, Urology, and Wound Care. The company focuses on addressing the unmet therapeutic needs of the topical anti-infective market. Its commercial products include the Neutrox family of products, including Avenova for the eye care market; Neutrophase for wound care; and CelleRx for the dermatology market. The company’s products under development stage consist of Aganocide compounds, which are novel, synthetic anti-infectives designed to mimic the body’s defense against infection and developed to treat and prevent a range of local, non-systemic infections with a low likelihood of developing bacterial resistance. It has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds that cover various dermatological conditions. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

32 Employees
Last Reported Date: 03/26/15
Founded in 2000

novabay pharmaceuticals inc (NBY) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $478.5K
Chief Financial Officer, Treasurer and Secret...
Total Annual Compensation: $318.8K
Senior Vice President of Business and Corpora...
Total Annual Compensation: $281.3K
Compensation as of Fiscal Year 2014.

novabay pharmaceuticals inc (NBY) Key Developments

NovaBay Pharmaceuticals, Inc. - Special Call

To feature key opinion leaders in both ophthalmology and optometry and a discussion of its commercialization strategy

NovaBay Pharmaceuticals, Inc. Presents at Marcum Microcap Conference 2015, May-27-2015 02:00 PM

NovaBay Pharmaceuticals, Inc. Presents at Marcum Microcap Conference 2015, May-27-2015 02:00 PM. Venue: Grand Hyatt New York, Park Avenue at Grand Central, New York, NY 10017, United States.

Novabay Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for First Quarter Ended March 31, 2015

NovaBay Pharmaceuticals, Inc. announced unaudited consolidated earnings results for first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $46,000, operating loss of $4,661,000, net loss of $4,640,000 or $0.09 basic and diluted per share, compared to the total revenue of $100,000, operating loss of $4,078,000, net loss of $3,565,000 or $0.08 basic and diluted per share, for the same quarter a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBY:US $0.65 USD +0.0201

NBY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NBY.
View Industry Companies
 

Industry Analysis

NBY

Industry Average

Valuation NBY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.3x
Price/Book 17.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVABAY PHARMACEUTICALS INC, please visit www.novabaypharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.